Zoetis Inc. and Exelixis, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: Zoetis Inc. vs. Exelixis, Inc.

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic growth. Over the past decade, Zoetis Inc. and Exelixis, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Zoetis Inc. consistently allocated a significant portion of its budget to SG&A, with a peak in 2023, reaching approximately 2.15 billion USD. This represents a steady increase of about 31% from 2014. In contrast, Exelixis, Inc. exhibited a more aggressive growth in SG&A spending, skyrocketing by over 900% during the same period, culminating in 2023 with expenses around 543 million USD. This divergence highlights Zoetis's stable investment strategy versus Exelixis's rapid expansion approach, reflecting their unique market strategies and growth trajectories.